# Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

> **NCT06363734** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 32 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- EGFR Activating Mutation
- Cell Cycle Deregulation
- EGFR-TKI Resistant Mutation

## Interventions

- **DRUG:** Osimertinib plus Dalpiciclib

## Key facts

- **NCT ID:** NCT06363734
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-09
- **Primary completion:** 2025-12-15
- **Final completion:** 2026-12-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06363734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06363734, "Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06363734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*